Identification of various molecules involved in cell cycle control has demonstrated a close association between regulation of the cell cycle and neoplastic transformation. Thus, derangements in the cell cycle machinery may play a critical role in oncogenesis and contribute to uncontrolled cell growth.
Recent results indicate that an inhibitor of the cell cycle, the p16 protein, may be a new tumour suppressor. The gene encoding p16, denoted either MTS1 (multiple tumour suppressor 1) (Kamb et al., 1994) , CDK41 (Nobori et al., 1994) or CDKN2 (The HUGO Nomenclature Comittee designation), is localised to human chromosome segment 9p21, a region frequently found to contain cytogenetic abnormalities in several types of cancer, including malignant melanomas, gliomas, lung carcinomas and leukaemias (Kamb et al., 1994; Nobori et al., 1994) . Moreover, the gene has been found to be homozygously deleted or mutated in a high percentage of cell lines derived from tumours of various histological types (Kamb et al., 1994) . On this background CDKN2 has been suggested to be involved in the formation of malignancies originating from a wide range of tissues (Kamb et al., 1994). p16 was originally identified when searching for proteins able to associate with the cell cycle regulating enzyme cyclindependent kinase 4 (cdk4) (Serrano et al., 1993) . Cdk4 is, when activated by cyclin Dl, able to phosphorylate the retinoblastoma tumour-suppressor protein (pRb), resulting in release of pRb-mediated GI arrest. Since p16 can bind to cdk4 and thereby inhibit the catalytic activity of the cyclin Dl-cdk4 complex, the protein seems to participate in a regulatory pathway together with cdk4, cyclin Dl and pRb. Alterations of cyclin Dl and cdk4 have also been suggested to be involved in oncogenesis (Khatib et al., 1993; Motokura and Arnold, 1993) . Thus, translocations involving the ql3 segment of chromosome 11, harbouring the cyclin Dl gene (CCNDI), have frequently been observed in parathyroid adenomas and B-cell lymphomas (Motokura and Arnold, 1993) . In addition, CCND1 has been found amplified and overexpressed in breast (Lammie et al., 1991) and oesophageal carcinomas (Jiang et al., 1992) . Similarly, the amplification and overexpression of CDK4, localised to chromosome band 12q13, has been suggested to contribute to deranged growth control in some sarcomas (Khatib et al., 1993; Forus et al., 1995) .
As (Cairns et al., 1994; Spruck et al., 1994 (Maniatis et al., 1982) . Aliquots (7 fig) of DNA were digested with HindIII, separated on 0.8% agarose gels and transferred by alkaline blotting onto Hybond N+ membranes (Amersham, Amersham, UK), according to the manufacturer's manual. After UV cross-linking for 5 min, the blots were prehybridised for 2 h and subsequently hybridised with DNA probes labelled with 32P by the random primer technique (Feinberg and Vogelstein, 1983) . The hybridisation was carried out in 50% formamide, 6 x standard saline citrate (20 x SSC = 3.0 M sodium chloride, 0.3 M sodium citrate), 0.5% sodium dodecyl sulphate (SDS), 1.5 x Denhardt's (50 x Denhardt's = 1% Ficoll, 1% bovine serum albumin, 1% polyvinylpyrrolidone) and 100 jig ml1 denatured salmon sperm DNA at 42°C over night as described by Maniatis et al. (1982) . After hybridisation, the membranes were washed for 20 min at 65°C subsequently in 2 x SSC/0.5% SDS, 1 x SSC/0.5% SDS and 0.5 x SSC/0.5% SDS. For multiple hybridisations, the bound probe was removed by incubating the filters for 15 min at room temperature in 100 mM sodium hydroxide and 1 mM sodium EDTA.
Samples with a signal weaker than 25% when compared with the signal from a reference lane were scored as having a homozygous deletion of the corresponding gene. A signal at least 3-fold more intense than signals from samples with a normal copy number of the gene was scored as an amplification. Densitometric analysis of the autoradiograms was used to decide in cases that were not obvious. To adjust for unequal amounts of loaded DNA, the blots were rehybridised to a control probe encoding apolipoprotein B, located on chromosome 2.
Northern blot analysis Total cellular RNA was prepared by the guanidinium thiocyanate-caesium chloride method described by Maniatis et al. (1982) . Samples of 5 tg of total RNA were separated by 1% agarose-formaldehyde gel electrophoresis and blotted onto HybondN+membranes (Amersham, Amersham, UK) according to the manufacturer's manual. After baking for 2 h and subsequent ultraviolet cross-linking, the filters were hybridised with DNA probes labelled with 32P by the random primer method (Feinberg and Vogelstein, 1983) . The hybridisations were carried out in 0.5 M sodium phosphate (pH 7.2), 7% SDS and 1 mM sodium EDTA overnight at 65°C as described by Church and Gilbert, (1984) . The membranes were subsequently washed three times for 15 min in 40 mM sodium phosphate (pH 7.2) and 1% SDS. For multiple hybridisations the bound probe was removed by incubating the filters twice for 5 min in 0.1 x SSC and 0.1% SDS at 95-100°C.
To correct for uneven amount of RNA loaded in each lane, the filters were rehybridised with a kinase-labelled (Maniatis et al., 1982) oligonucleotide probe specific for human 18S rRNA. The mRNA expression levels were classified as follows: '-/ +', undetectable/low expression; '+ +' and '+ + +', high or very high expression.
Probes
The following probes were used: CCND1 cDNA kindly provided by Dr D Beach, Howard Hughes Medical Institute, Cold Spring Harbor, NY, USA; and CDK4 cDNA by Dr P Meltzer, National Institute of Health, Bethesda, MD, USA. As probe for CDKN2 a 929 bp PCR product was used, amplified from a plasmid encoding the CDKN2 cDNA (Dr D Beach) with primers suggested by Kamb et al. (1994) . The APOB clone pB27, kindly provided by Dr J Breslow, Rockefeller University, New York, NY, USA, and a human specific oligonucletide probe complementary to nucleotides 287-305 of 18S rRNA were used as control probes for the Southern and Northern blots respectively.
Results
Southern blot analysis DNA from 109 human sarcomas of various histological subtypes was analysed for homozygous deletions of the putative tumour-suppressor gene CDKN2 and for amplification of CDK4 and CCDN1 (Table I and Figure 1 ). Homozygous deletion of CDKN2 was found in eight tumours (7%), including two rhabdomyosarcomas, two malignant Schwannomas, one chondrosarcoma, one leiomyosarcoma, one osteosarcoma and one non-classified sarcoma. Six of these samples were obtained directly from patients (6/77 = 8%), one specimen was a xenograft (1/27 = 4%) and one was a cultured cell line (1/5 = 20%).
Amplification of CDK4 was observed in 12 cases, including four lipo-, two osteo-and two fibrosarcomas and in one haemangiopericytoma, malignant Schwannoma, rhabdomyosarcoma and a non-classified sarcoma. CCND1 amplification was found in only four cases: one osteosarcoma, one haemangiopericytoma, one liposarcoma and one non-classified sarcoma. Interestingly, none of the tumours with CDKN2 deletions showed amplification of any of the two other genes, whereas three of the four cases with amplified CCND1 also had amplification of CDK4. When adding up the alterations involving the CDKN2, CDK4 and CCND1 genes, the total number of aberrations in this pathway increases to 21 cases (Table I) .
Northern blot analysis To examine the association between DNA status and gene expression at the mRNA level, total RNA was extracted from 100 of the 109 tumours and from a panel of 12 different normal tissue samples.
As expected, no CDKN2 mRNA was detected in tumours with homozygous deletion of the gene, whereas these cases expressed variable amounts of mRNA for both cdk4 and cyclin Dl (Figure 2 and Table I ). Interestingly, although none of the 12 normal tissues examined expressed detectable levels of the CDKN2 transcript, 33 of the sarcomas (33%) showed high to very high mRNA levels ('+ +' or '+ + +'), of which 18 were patient biopsies (14 primary tumours and four metastatic lesions, i.e. 26% of the patient biopsies), whereas 13 originated from xenografts (48% of the xenografts) and two were in vitro cell lines (50%) ( Table II) .
All 12 tumours with CDK4 amplification demonstrated a high ('+ +' or '+ + +') transcript level, and 11 of these tumours showed a concomitant high expression of one of the two other genes (Figure 2 and Table I ). Moreover, high ('+ +') CDK4 expression was found also in nine tumours without amplification of the gene (Table II) . Altogether, elevated CDK4 transcript levels were present in biopsies from 11 patients (16%), in seven sarcoma xenografts (26%) and in three in vitro cell lines (75%). The expression levels in normal tissues varied. Thus, specimens obtained from kidney, lung, ovary and breast gland showed a high ('+ +') expression, whereas the other tissues demonstrated a low, but detectable ('+') CDK4 mRNA level.
Except for lung and skin, the mRNA level of CCND1 was generally low in the normal tissues. In contrast, high expression levels were found in 37 sarcomas (37%), of which 24 were tumour biopsies (35% of the patient biopsies), 12 xenografts (44%) and one of four cultured cell lines (Table   II To investigate whether CDKN2 aberations might be involved in the tumorigenesis of human sarcoma, a panel of more than 100 tumours of various histological subtypes was analysed for homozygous deletions of the gene. It was found that only eight of the sarcomas showed such deletions.
Notably, no deletion of CDKN2 was seen in any of the 21 liposarcomas and 20 MFHs studied, and in only one of 21 osteosarcomas. The low deletion frequency stands in contrast to the 25-87% homozygous deletions found in various human tumour cell lines, including 60% of the human osteosarcoma cell lines studied (Kamb et al., 1994; Nobori et al., 1994) . Interestingly, however, we found that two of eight malignant Schwannomas and two of five rhabdomyosarcomas had lost CDKN2, suggesting that homozygous deletions of CDKN2 might be of different importance in the development of various sarcoma subtypes. The overall low incidence of deletions found here is in accordance with the results of Spruck et al. Cairns et al. (1994) , who observed homozygous deletions that included the CDKN2 gene only in about 10-20% of bladder, brain, head and neck and lung carcinomas. Conceivably, the high deletion frequency observed in cell lines might be a result of in vitro cell cultivation. Our data do not permit any conclusions on this, but it was found that one of five sarcoma cell lines had lost the CDKN2 gene, whereas only one of 27 (4%) sarcomas (1994) . The possibility exists that the somewhat contradicting reports concerning the incidence of homozygous CDKN2 deletions might in part be related to methodological factors. Despite careful dissection of the tumour tissue before freezing, infiltration of normal cells in the tumour biopsy could result in a low observed deletion frequency. However, Southern blot analysis, as used here, should be less sensitive to a moderate contribution from normal tissue than the PCR analysis used by others (Cairns et al., 1994; Kamb et al., 1994; Nobori et al., 1994; Spruck et al., 1994) . Furthermore, it should be noted that part of our sarcoma material has previously been analysed for loss of heterozygosity of the TP53 gene without any indications of normal cell DNA affecting the results (Andreassen et al., 1993 small-cell lung (Hayashi et al., 1994) and pancreatic carcinomas (Caldas et al., 1994) . Thus, in order to reveal whether such abnormalities may be important in the tumorigenicity of sarcomas, the tumours will be analysed for mutations in exon 1 and 2.
The mechanism of action of the p16 inhibitor made it of interest to examine the tumour panel for aberrations also in the genes encoding cdk4 and cyclin Dl. CDK4 has previously been found amplified in sarcoma cell lines (Khatib et al., 1993) and tumour biopsies (Forus et al., 1995) . Moreover, deregulation of the CCND1 gene has been observed in several cancer forms, caused either by tumour-specific gene translocation (Motokura and Arnold, 1993) or by gene amplification (Lammie et al., 1991) . CDK4 is located in the q13-14 region of human chromosome 12, and amplification of genes in this chromosomal segment has frequently been observed in human sarcomas (Forus et al., 1993; Demetrick et al., 1994) . In the present work, CDK4 amplification was observed in 12 cases, and in three of these tumours CCND1 was also amplified. It might be speculated that there is a synergistic growth advantage when both genes are amplified. Amplification of CDK4 and/or of CCND1 found in the tumour biopsies was never accompanied by CDKN2 deletion. This is in accordance with the view that this growthregulating pathway can be deregulated either by a loss of the inhibitor or by an increase in the amount of the rate-limiting cyclin Dl/cdk4 complex. Most of our samples have been examined for amplification also of the two other D-type cyclins, cyclin D2 and cyclin D3, both able to form a complex with cdk4 in a similar way as cyclin DI (Bates et al., 1994) . These genes were amplified in only one case each, both concomitant with amplification of CDK4 but not of CCND1 (results not shown).
The mRNA levels of CDK4, CCND1 and CDKN2 were examined in an attempt to detect possible consistent patterns of co-variation between the three transcripts, and to relate the results to the DNA status. Although caution must be taken when drawing conclusions on the activity of their associated gene products, it has been reported that the amount of cyclin Dl -cdk4 complex varies in relation to the CDK4 mRNA levels (Pines, 1993) and that synthesis of cyclin Dl, a protein with short half-life, is necessary and rate limiting for GI progression (Matsushime et al., 1991; Baldin et al., 1993; Hunter and Pines, 1994) . Taken together, this indicates that the mRNA levels might be informative for the protein activities.
Interestingly, and surprisingly for a cell cycle inhibitor, 33% of our tumours showed large amounts of CDKN2 mRNA compared with undetectable levels in all normal tissue samples examined. Moreover, in 25 of the 33 cases, high inhibitor mRNA expression was accompanied by absent or only negligible levels of the CCND1 transcript. Conversely, most of the sarcomas with high cyclin Dl expression (37%) showed low expression of the inhibitor, suggesting an inverse relationship between these two transcripts. The tumourpromoting effects of p16, cdk4 or cyclin Dl aberrations are mnct lit-plu AlIIA tn th,.ir^Ivrvne thn, _crfle; the retinoblastoma protein, and thus on entry into S-phase. The cdk4 inhibitor is suggested to function as a negative regulator of cdk4 once pRb has been inactivated by phosphorylation (Serano et al., 1993) . In cells in which the pRb tumour-suppressor protein is constitutively inactivated, p16 expression is hypothesised to be elevated with a subsequent inhibition of the kinase (Serrano et al., 1993) . Furthermore, it has been shown that the CCND1 expression may be positively regulated at the transcriptional level by active, unphosphorylated pRb (Bates et al., 1994; Hunter and Pines, 1994; Muller et al., 1994) . Therefore, it seems reasonable to assume that cells with low expression of CCND1 and elevated expression of CDKN2 may be pRb deficient, and studies to examine this hypothesis have been initiated.
Only 4 of the 37 sarcomas with elevated CCND1 mRNA levels had amplification of the gene. Similarly, in breast carcinomas elevated levels of cyclin Dl mRNA and protein have been found to occur without concomitant gene aberrations, suggesting that other molecular mechanisms may induce overexpression of the cyclin Dl gene (Buckley et al., 1993; Bartkova et al., 1994) . Elevated cyclin Dl expression may overcome pRb-mediated growth inhibition, as has been demonstrated in oesophageal (Jiang et al., 1993) and nonsmall-cell lung carcinomas (Schauer et al., 1994) . It has been speculated whether other mechanisms than cyclin Dl-cdk4 mediated pRb phosphorylation may be involved, as no phosphorylated tumour-suppressor protein was detected when cyclin Dl and pRb were cotransfected into SaOS-2 cells (Hinds et al., 1992; Dowdy et al., 1993) . Thus, it is possible that such mechanisms might help explain the high fraction of sarcomas expressing elevated levels of cyclin Dl mRNA.
In summary, although the overall frequency of homozygous deletions of CDKN2 was found to be low in sarcomas, the indication of a higher incidence of such deletions among the malignant Schwannomas and rhabdomyosarcomas suggests that inactivation of the gene may be of particular significance in the development of these sarcoma subtypes. The overexpression of CDKN2 observed in a considerable fraction of all the sarcomas studied might be related to pRb deficiency or to mechanisms stabilising the mRNA. Moreover, the high fraction of sarcomas with amplification and/or increased mRNA levels of CDK4 and CCND1 further supports the view that disturbance of this pathway may be of importance in the tumorigenesis of sarcomas. Abbreviations CDK4, cyclin-dependent kinase 4; CDKN2, the cdk4 inhibitor, p16; CCNDI, cyclin Dl; APOB, apolipoprotein B; pRb, retinoblastoma protein; MFH, malignant fibrous histiocytoma, SDS, sodium dodecyl sulphate; SSC, standard saline citrate; PCR, polymerase chain reaction
